HuMax-TAC-ADC

HuMax®-TAC-ADC (also known as ADCT-301) is an antibody-drug conjugate (ADC) combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. HuMax-TAC-ADC targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, which makes it a very attractive target for antibody-payload approaches. HuMax-TAC-ADC has the potential to be a first-in-class antibody-drug conjugate for the treatment of CD25-expressing lymphomas and leukemias. HuMax-TAC-ADC is in development for lymphoma under an agreement between Genmab and ADC Therapeutics.

Back to top

Lymphoma is a type of cancer that starts in the white blood cells (lymphocytes), which are part of the body’s immune system. There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. National Cancer Institute statistics estimate that 9,050 people will be diagnosed with Hodgkin lymphoma and 71,850 people will be diagnosed with non-Hodgkin lymphoma in the United States in 2015.

In March 2015, ADC Therapeutics filed an Investigational New Drug application (IND) for HuMax-TAC-ADC for a Phase I trial in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma.


Back to top

Acute myeloid leukemia (AML) begins in the bone marrow and often moves quickly into the blood. It may then spread to other parts of the body including the lymph nodes, liver, spleen and central nervous system1.  The average age of AML patients is 67, with the disease uncommon in people under 452. According to the American Cancer Society, there will be 19,950 new cases of AML in the United States in 20162.


1 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/overviewguide/leukemia-aml-overview-what-is-aml
2 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-key-statistics


Back to top